Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03719690
Title Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Kura Oncology, Inc.

oral squamous cell carcinoma

head and neck squamous cell carcinoma

nasopharynx carcinoma

laryngeal squamous cell carcinoma

paranasal sinus cancer

pharynx squamous cell carcinoma



Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL | AUT

Additional content available in CKB BOOST